|
|
|
| Effect of Huachansu Capsule Combined with NX Chemotherapy on Serum Related Tumor Markers and Median Survival in Patients with Advanced Breast Cancer |
| CHEN Hao |
| Liaoyang General Hospital of Petrochemicals, Liaoning Liaoyang 111003, China |
|
|
|
|
Abstract Objective: To investigate the effect of Huachansu capsule combined with NX chemotherapy on serum-related tumor markers and median survival in patients with advanced breast cancer. Methods: From February 2014 to April 2016, 92 patients with advanced breast cancer were enrolled in our hospital. As the random number table method, they were divided into control group (n=46) and experimental group (n=46). The control group was given NX chemotherapy (capecitabine + vinorelbine). On this basis, the experimental group was given Huachansu capsule for 2 consecutive treatments. The therapeutic effects, adverse reactions, and Karnofsky functional status score (KPS) were observed in the two groups. Serum tumor markers [saccharide antigen 15-3 (CA153), carcinoembryonic antigen (CEA)] and metastasis-invasive indicators before and after treatment [matrix metal] Protease-9 (MMP-9), vascular endothelial growth factor (VEGF)], and two-year follow-up of the two groups of patients, the median survival (OS), median progression-free survival (PFS) were compared. Results: There was no significant difference between the RR group and the control group (P>0.05). The difference of serum CA153, CEA, VEGF and MMP-9 between the two groups was more significant than that of the control group (P<0.05); Both groups of adverse reactions were grade II-III. The incidence of thrombocytopenia, anemia, and neutropenia in the experimental group was lower than that in the control group (P<0.05). The improvement rate of KPS score in the experimental group was higher than that in the control group (P<0.05); After treatment During the 2-year follow-up, the median OS and median PFS in the experimental group were greater than those in the control group (P<0.05). Conclusion: Huachansu capsule combined with NX chemotherapy in the treatment of patients with advanced breast cancer is effective, can reduce adverse reactions, reduce serum CA153, CEA, VEGF, MMP-9 levels, improve quality of life, and prolong the survival of patients
|
|
|
|
|
|
[1] 魏薇,张增梅,赵海运,等.射线防护在术中放疗联合乳腺癌保乳术中应用效果观察[J].郑州大学学报(医学版),2018,53(5):671~674.
[2] Miolo G,Muraro E,Martorelli D,et al.Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients[J].BMC Cancer,2014,14(1):954.
[3] 陈孝平,汪建平.外科学[M].第8版.北京:人民卫生出版社,2013.255~256.
[4] 郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002.364~366.
[5] 刘海霞.紫杉醇联合卡铂化疗同步放疗治疗中晚期宫颈癌近期疗效观察[J].山东医药,2017,57(6):83~84.
[6] 闻国权,吴淑仪,黎冠宏.赫赛汀联合阿霉素脂质体治疗HER-2阳性乳腺癌的肿瘤负荷及毒副反应评估[J].海南医学院学报,2016,22(23):2869~2872.
[7] Andreopoulou E.Chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer:an overview[J].Curr Breast Cancer Rep,2013,5(1):42~50.
[8] 祝朝富,李卓虹,安佰平,等.长春瑞滨联合卡培他滨或替吉奥治疗紫杉类及蒽环类耐药晚期乳腺癌的效果分析[J].临床肿瘤学杂志,2017,22(3):227~231.
[9] 田柳.华蟾素胶囊辅助治疗晚期乳腺癌疗效及耐受性观察[J].西南国防医药,2017,27(11):1173~1175.
[10] 邓爽,冯国斌,徐久东,等.华蟾素胶囊联合含卡培他滨基础方案治疗晚期乳腺癌疗效及耐受性观察[J].药学与临床研究,2017,25(5):439~443.
[11] 王娜,徐小艳,杨金花,等.联合检测VEGF,MMP-2和MMP-9对乳腺癌的诊断和恶性程度的评估[J].中国体视学与图像分析,2017,22(2):238~243. |
|
|
|
2019, Vol. 25 
